CN103649126B - 用于调节铁稳态的组合物及其使用方法 - Google Patents

用于调节铁稳态的组合物及其使用方法 Download PDF

Info

Publication number
CN103649126B
CN103649126B CN201280013021.6A CN201280013021A CN103649126B CN 103649126 B CN103649126 B CN 103649126B CN 201280013021 A CN201280013021 A CN 201280013021A CN 103649126 B CN103649126 B CN 103649126B
Authority
CN
China
Prior art keywords
composition
fusion protein
seq
amino acid
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201280013021.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN103649126A (zh
Inventor
赫伯特·Y·林
朱迪·L·巴比特
特蕾西·曼哈尔
帕特里克·吉尔林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
FERRUMAX PHARMACEUTICALS Inc
General Hospital Corp
Original Assignee
FERRUMAX PHARMACEUTICALS Inc
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by FERRUMAX PHARMACEUTICALS Inc, General Hospital Corp filed Critical FERRUMAX PHARMACEUTICALS Inc
Priority to CN201610908297.0A priority Critical patent/CN107022032A/zh
Publication of CN103649126A publication Critical patent/CN103649126A/zh
Application granted granted Critical
Publication of CN103649126B publication Critical patent/CN103649126B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Obesity (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
CN201280013021.6A 2011-01-19 2012-01-19 用于调节铁稳态的组合物及其使用方法 Expired - Fee Related CN103649126B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610908297.0A CN107022032A (zh) 2011-01-19 2012-01-19 用于调节铁稳态的组合物及其使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161434405P 2011-01-19 2011-01-19
US61/434,405 2011-01-19
PCT/US2012/021829 WO2012150973A1 (en) 2011-01-19 2012-01-19 Compositions for regulating iron homeostasis and methods of using same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201610908297.0A Division CN107022032A (zh) 2011-01-19 2012-01-19 用于调节铁稳态的组合物及其使用方法

Publications (2)

Publication Number Publication Date
CN103649126A CN103649126A (zh) 2014-03-19
CN103649126B true CN103649126B (zh) 2016-11-09

Family

ID=47107987

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201280013021.6A Expired - Fee Related CN103649126B (zh) 2011-01-19 2012-01-19 用于调节铁稳态的组合物及其使用方法
CN201610908297.0A Pending CN107022032A (zh) 2011-01-19 2012-01-19 用于调节铁稳态的组合物及其使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201610908297.0A Pending CN107022032A (zh) 2011-01-19 2012-01-19 用于调节铁稳态的组合物及其使用方法

Country Status (8)

Country Link
US (2) US9708379B2 (enExample)
EP (1) EP2665752B1 (enExample)
JP (2) JP2014506452A (enExample)
KR (1) KR102035357B1 (enExample)
CN (2) CN103649126B (enExample)
AU (3) AU2012251919B2 (enExample)
CA (1) CA2825163C (enExample)
WO (1) WO2012150973A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110070242A1 (en) * 2009-09-01 2011-03-24 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods for Diagnosing and Treating Iron Dysregulation
CN104136462B (zh) * 2011-12-14 2017-06-09 艾伯维德国有限责任两合公司 用于诊断和治疗铁相关病症的组合物和方法
MX357708B (es) 2011-12-14 2018-07-20 Abbvie Deutschland Composicion y metodo para el diagnostico y tratamiento de trastornos relacionados con hierro.
UY36449A (es) 2014-12-19 2016-07-29 Novartis Ag Composiciones y métodos para anticuerpos dirigidos a bmp6
WO2017123642A1 (en) * 2016-01-12 2017-07-20 The Trustees Of The University Of Pennsylvania Methods and uses of osteoclast associated receptor (oscar) for prevention and treatment of osteoarthritis
WO2017216724A1 (en) 2016-06-15 2017-12-21 Novartis Ag Methods for treating disease using inhibitors of bone morphogenetic protein 6 (bmp6)
WO2019136043A1 (en) * 2018-01-03 2019-07-11 Acceleron Pharma Inc. Single-arm co-receptor fusion proteins and uses thereof
CA3156007A1 (en) 2019-09-27 2021-04-01 Disc Medicine, Inc. METHODS OF TREATING MYELOFIBROSE AND ASSOCIATED CONDITIONS
US20230061804A1 (en) * 2020-01-23 2023-03-02 The Rockefeller University Phase separation sensors and uses thereof
US12508262B2 (en) 2020-04-30 2025-12-30 Keros Therapeutics, Inc. Methods of using ALK2 inhibitors
ES3075793T3 (en) 2020-05-13 2026-08-07 Disc Medicine Inc Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis
AU2021273014A1 (en) 2020-05-13 2022-11-17 AbbVie Deutschland GmbH & Co. KG Anti-hemojuvelin (HJV) antibodies for treating anemia of chronic disease
WO2022098812A1 (en) 2020-11-04 2022-05-12 Keros Therapeutics, Inc. Methods of treating iron overload
WO2022271716A2 (en) * 2021-06-21 2022-12-29 Keros Therapeutics, Inc. Methods of using activin receptor type ii signaling inhibitors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006088972A2 (en) * 2005-02-16 2006-08-24 The General Hospital Corporation Use of modulatirs of compounds of tgf-beta superfamily to regulate hepcidin-mediated iron metabolism
WO2008124768A1 (en) * 2007-04-09 2008-10-16 The General Hospital Corporation Hemojuvelin fusion proteins and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5731168A (en) * 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US7459540B1 (en) * 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
EP1618131A2 (en) * 2003-04-15 2006-01-25 Xenon Pharmaceuticals Inc. Juvenile hemochromatosis gene (hfe2a), expression products and uses thereof
CA2549477A1 (en) * 2005-06-29 2006-12-29 The Regents Of The University Of California Competitive regulation of hepcidin mrna by soluble and cell-associated hemojuvelin
EP1806365A1 (en) 2006-01-05 2007-07-11 Boehringer Ingelheim International GmbH Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them
US7528111B2 (en) * 2006-05-12 2009-05-05 Bristol-Myers Squibb Company Method of vaccinating subjects receiving immune modulating therapy
EP1862555A1 (en) 2006-05-29 2007-12-05 Klinikum der Universität Regensburg Means and methods for diagnosing cancer or a corresponding predisposition
CN101307085B (zh) * 2007-08-01 2012-06-13 香港理工大学深圳研究院 抑制铁调素调节蛋白的siRNA、重组慢病毒及其应用
EP2033971A1 (de) * 2007-09-06 2009-03-11 Abbott GmbH & Co. KG Bone Morphogenetic Protein (BMP)-bindende Domänen von Proteinen der Repulsive Guidance Molecule (RGM) Proteinfamilie und funktionale Fragmente davon sowie deren Verwendung
EP2235054A1 (en) * 2007-12-13 2010-10-06 Merck Serono S.A. Sarp-1 fusion proteins and uses thereof
WO2009152944A1 (en) * 2008-05-29 2009-12-23 Hanall Pharmaceutical Co., Ltd Modified erythropoietin (epo)polypeptides that exhibit increased protease resistance and pharmaceutical compositions thereof
CA2742871C (en) * 2008-11-13 2018-10-23 Herb Lin Methods and compositions for regulating iron homeostasis by modulation of bmp-6

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006088972A2 (en) * 2005-02-16 2006-08-24 The General Hospital Corporation Use of modulatirs of compounds of tgf-beta superfamily to regulate hepcidin-mediated iron metabolism
WO2008124768A1 (en) * 2007-04-09 2008-10-16 The General Hospital Corporation Hemojuvelin fusion proteins and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
铁调素调节蛋白(HJV)- 一个新的铁代谢调节蛋白;钱忠明等;《生物化学与生物物理进展》;20060420;第33卷(第3期);226-230 *

Also Published As

Publication number Publication date
AU2012251919A1 (en) 2013-08-15
CN107022032A (zh) 2017-08-08
JP2014506452A (ja) 2014-03-17
AU2017201782A1 (en) 2017-03-30
EP2665752A1 (en) 2013-11-27
CN103649126A (zh) 2014-03-19
AU2017201782B2 (en) 2019-01-17
WO2012150973A9 (en) 2013-01-17
AU2012251919A2 (en) 2014-06-12
JP2017025070A (ja) 2017-02-02
KR20140030134A (ko) 2014-03-11
KR102035357B1 (ko) 2019-10-23
US20180044389A1 (en) 2018-02-15
WO2012150973A1 (en) 2012-11-08
US9708379B2 (en) 2017-07-18
CA2825163C (en) 2019-12-03
US10273273B2 (en) 2019-04-30
AU2019202913A1 (en) 2019-05-16
EP2665752A4 (en) 2014-09-17
US20140199302A1 (en) 2014-07-17
JP6466376B2 (ja) 2019-02-06
CA2825163A1 (en) 2012-11-08
AU2012251919B2 (en) 2016-12-15
EP2665752B1 (en) 2018-10-10

Similar Documents

Publication Publication Date Title
JP6466376B2 (ja) 鉄恒常性を制御するための組成物およびそれを用いる方法
US10869909B2 (en) Compositions and methods of use for treating metabolic disorders
EP3068425B1 (en) Methods of using interleukin-10 for treating diseases and disorders
US10610568B2 (en) Compositions and methods of use for treating metabolic disorders
CN1823088B (zh) 结合红细胞生成素受体的新肽
JP2019123719A (ja) インターロイキン−１０を疾病及び疾患の治療に用いる方法
US20020058619A1 (en) Ligand for vascular endothelial growth factor receptor
WO2014176373A2 (en) Interleukin-10 compositions and uses thereof
JPH0542413B2 (enExample)
CN106573072A (zh) 降低血清胆固醇的方法
AU2015336101A1 (en) Methods of using interleukin-10 for treating diseases and disorders
JP2022513776A (ja) インスリン受容体結合親和性が低下したインスリンアナログ
WO2015031316A1 (en) Methods of using interleukin-10 for treating diseases and disorders
US20160375100A1 (en) Protease-resistant mutants of stromal cell derived factor-1 in the repair of tissue damage
CA2969574A1 (en) Methods of improving yield in recombinant protein production
JP2023512587A (ja) Ｐａｎｘ１関連疾患の治療
US11179444B2 (en) Glucagon analogs and methods of use thereof
HK1241391A1 (en) Compositions for regulating iron homeostasis and methods of using same
KR20140084191A (ko) 멜라노트란스페린으로부터 유도된 펩티드 화합물 및 이의 용도
WO2014014816A2 (en) Methods of treating glucose metabolism disorders
HK1206260B (en) Compositions and methods of use for treating metabolic disorders

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20161109

Termination date: 20210119